New study tracks Real-World safety of triple therapy for Low-Volume prostate cancer
NCT ID NCT06661122
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 29 times
Summary
This study looks at medical records of 100 Japanese men with low-volume metastatic hormone-sensitive prostate cancer who are taking darolutamide plus standard hormone therapy and chemotherapy. Researchers want to see how safe the combination is and how well it controls the cancer in everyday medical practice. No extra visits or treatments are required—just routine care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Many locations
RECRUITINGMultiple Locations, Japan
Conditions
Explore the condition pages connected to this study.